The university said it studied two dosing regimes in early trials.
London:
Oxford ‘s COVID-19 vaccine candidate has a better immune response when a two-dose system is used than a full-dose and a half-dose increase, the university said Thursday.
The candidate of the vaccine, which was approved to AstraZeneca, has published the results of an interim end-of-period test showing higher efficacy when a half-dose is followed by a full dose, compared to two full-dose rules, although more work is needed to determine the outcome.
Details from the Phase I / II clinical trials released on Thursday made no mention of the half-dose / full-dose regimen, which Oxford has said was “unplanned” but on agree with regulators.
The university said it had studied two dosing regimens in early-stage trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, studied as a “sad dose” strategy. could be.
“The increased doses of the vaccine have been shown to induce stronger antibody responses than a single dose, the standard dose / standard dose stimulating the optimal response,” the university said in a statement.
The vaccine “stimulates broad-spectrum and T-cell antibody activity,” he said after releasing further data from Phase I / II clinical trials.
(Except for the headline, this story was not edited by NDTV staff and is published from syndicated food.)